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Abstract 28 
Chronic bacterial lung infections associated with non-cystic fibrosis bronchiectasis represent a 29 
substantial and growing healthcare burden. Where Pseudomonas aeruginosa is the numerically 30 
dominant species within these infections, prognosis is significantly worse. However, in many 31 
individuals, Haemophilus influenzae predominates, a scenario associated with less severe disease. 32 
The mechanisms that determine which pathogen is most abundant are not known.  33 
We hypothesised that the distribution of H. influenzae and P. aeruginosa would be consistent with 34 
strong interspecific competition effects. Further, we hypothesised that where P. aeruginosa is 35 
predominant, it is associated with a distinct ‘accessory microbiota’ that reflects a significant interaction 36 
between this pathogen and the wider bacterial community. To test these hypotheses, we analysed 37 
16S rRNA gene pyrosequencing data generated previously from 60 adult bronchiectasis patients, 38 
whose airway microbiota was dominated by either P. aeruginosa or H. influenzae. The relative 39 
abundances of the two dominant species in their respective groups were not significantly different, and 40 
when present in the opposite pathogen group the two species were found to be in very low 41 
abundance, if at all. These findings are consistent with strong competition effects, moving towards 42 
competitive exclusion. Ordination analysis indicated that the distribution of the core microbiota 43 
associated with each pathogen, readjusted after removal of the dominant species, was significantly 44 
divergent (ANOSIM, R = 0.07, P = 0.019). Taken together, these findings suggest that both 45 
interspecific competition and also direct and/or indirect interactions between the predominant species 46 
and the wider bacterial community, may contribute to the predominance of P. aeruginosa in a subset 47 
of bronchiectasis lung infections. 48 
 49 
 50 
 51 
 52 
 53 
 54 
55 
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Introduction 56 
The World Health Organization has reported that the global burden of diseases is shifting from 57 
communicable to non-communicable diseases, with chronic conditions such as heart disease, strokes, 58 
and lung diseases now being the chief causes of morbidity and mortality (Lopez et al., 2006). Among 59 
the great challenges in studying the causes and treatment of chronic lung infections, is a consequence 60 
of Koch’s postulates and the subsequent concept of infection pathogenesis summarized by the 61 
expression ‘one microbe, one disease’ (Nelson et al., 2013). Koch’s postulates have shaped our 62 
understanding of medical microbiology, as many important microbial diseases conform to them. 63 
However, that orthodoxy is being undermined by a growing recognition that diverse important 64 
diseases, including chronic lung infections, have a polymicrobial aetiology. This expanding 65 
understanding of chronic polymicrobial infections, originating from studies of cystic fibrosis airway 66 
microbiota, is beginning to be translated to other chronic lower respiratory diseases, including non-67 
cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis). 68 
Bronchiectasis is a chronic airway disease characterised by abnormal destruction and dilation 69 
of the large airways, bronchi and bronchioles (Cohen and Sahn, 1999). It is associated with chronic 70 
and frequently purulent expectoration, multiple exacerbations, and progressive dyspnoea that can 71 
become disabling (Ellis et al., 1981; Cohen and Sahn, 1999; Barker, 2002), and represents a 72 
substantial and growing healthcare burden. A recent US study demonstrated a marked increased 73 
prevalence in older populations varying from 4.2/100000 adults aged 18-34 years to 271.8/100000 74 
aged ≥ 75 years (Weycker et al., 2005). Bronchiectasis often goes unrecognized or is misdiagnosed 75 
as asthma or chronic obstructive pulmonary disease (COPD), leading to an underestimated 76 
prevalence. Despite this, bronchiectasis is associated with substantial socioeconomic cost due to the 77 
frequent use of primary and secondary healthcare resources. An US epidemiological study of 78 
bronchiectasis-associated hospitalizations from 1993 to 2006 demonstrated an average annual 79 
hospitalization rate of 16.5/100000 population with a significant annual increase of 2.4% in men and 80 
3.0% in women (Seitz et al., 2010), with the cost of managing bronchiectasis appearing to be rising 81 
(Joish et al., 2013). 82 
Airway inflammation resulting from chronic bacterial infection is thought to be a significant 83 
contributory factor driving disease progression in bronchiectasis (Barker, 2002). The perceived 84 
importance of bacterial pathogens in airway disease progression is reflected in the use of antibiotics 85 
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(Serisier and Martin, 2011; Serisier et al., 2013a), both as maintenance therapy, and to treat episodes 86 
of acute exacerbation. However, our understanding of the mechanisms that underpin relationships 87 
between infection by particular bacterial taxa and clinical outcomes is currently poor. This situation 88 
undermines the development of rationales for the selection of particular antibiotic treatment regimes 89 
(Serisier, 2012) or potentially specific anti-inflammatory therapy (Visser et al, 2012), and achieving 90 
better insight into the manner in which treatments achieve beneficial outcomes. While bronchiectasis 91 
can result from a variety of recognised aetiologies, it is often considered idiopathic. Recent studies 92 
have revealed a substantial and diverse bacterial microbiota (Rogers et al., 2013b; Tunney et al., 93 
2013; Rogers et al., 2014; van der Gast et al., 2014), which are typically dominated by either 94 
Haemophilus influenzae or Pseudomonas aeruginosa. Perhaps unsurprisingly given its colonisation of 95 
the upper airways in healthy individuals, H. influenzae is detectable in lower airway secretions from 96 
almost all bronchiectasis patients and is commonly the numerically dominant species (Rogers et al., 97 
2013b; Rogers et al., 2014). In contrast, P. aeruginosa dominated infections occur in a smaller number 98 
of patients (Rogers et al., 2014), but, are associated with an accelerated decline in lung function, more 99 
frequent pulmonary exacerbations, greater sputum production, and a higher requirement for antibiotic 100 
therapy (Evans et al., 1996; Ho et al., 1998; Shoemark et al., 2007; Rogers et al., 2014). 101 
A better understanding of the way in which P. aeruginosa interacts with the airway 102 
environment could provide important mechanistic insights into chronic infection in this patient group 103 
and in chronic respiratory infections more widely. Both the physiochemical characteristics of the airway 104 
environment, and the composition of the pre-existing lung microbiota, are likely to influence the 105 
likelihood of P. aeruginosa infection (Rogers et al., 2013a). Further, where P. aeruginosa dominates 106 
the infection microbiota, its growth is likely to further affect the composition of airway environment. 107 
This impact of colonisation could occur both directly through the metabolomic (Kozlowska et al., 2013) 108 
and secretomic (Bergamini et al., 2012) footprint of P. aeruginosa, and, in turn, indirectly by 109 
stimulating changes in the host immune response (Bergamini et al., 2012) and the activity of other co-110 
colonising species (Bakkal et al., 2010; Tashiro et al., 2013). Whilst the causality in these interactions 111 
is difficult to demonstrate, were such relationships to exist, they would result in both an association 112 
between P. aeruginosa infection and measures of airway disease, and an association between P. 113 
aeruginosa infection and microbiota composition. The first of these associations has been well 114 
documented. However, to our knowledge, there have been no investigations to assess the second. 115 
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We hypothesised that (1) the distribution of H. influenzae and P. aeruginosa in airways 116 
samples would be consistent with strong interspecific competition effects; i.e. when H. influenzae is 117 
the dominant species in a bronchiectasis lung infection, the population size of P. aeruginosa will be 118 
negatively impacted and vice versa when P. aeruginosa is dominant. (2) Where P. aeruginosa or H. 119 
influenzae is dominant species in a bronchiectasis lung infection, they are associated with distinct 120 
‘accessory microbiota’ that reflect a significant interaction between these pathogens and the wider 121 
bacterial community. To test these hypotheses, we analysed 16S rRNA gene pyrosequencing data, 122 
generated previously, from 60 adult bronchiectasis patients whose airway microbiota was dominated 123 
by either P. aeruginosa or H. influenzae. H. influenzae-dominated infections were chosen as a 124 
comparator group as they had been shown previously not to differ significantly in total bacterial load, 125 
dominant taxon relative abundance, or prior antibiotic burden (intravenous, oral, and combined), with 126 
those where P. aeruginosa was dominant (Rogers et al., 2014). Further, despite differences in disease 127 
course, these patients did not differ significantly in serum C-reactive protein (CRP) levels, or sputum 128 
IL-8 and IL-1β levels (Rogers et al., 2014) common markers of systemic and airway inflammation. To 129 
limit the potential effect of antibiotic therapy to influence microbiota composition (Serisier, 2013b), a 130 
sample set was chosen where there had been a four week period of clinical stability prior to collection, 131 
with no supplemental antibiotics administered (Serisier et al., 2013c). 132 
 133 
Materials and methods 134 
 The analysis performed here was based on 16S ribosomal RNA gene pyrosequencing data 135 
generated from induced sputum samples from adult patients with bronchiectasis, as part of the BLESS 136 
trial (Serisier et al., 2013c). These data are available through the Sequence Read Archive 137 
(http://www.ncbi.nlm.nih.gov/sra) under the accession number SRP0356. Details of patient 138 
recruitment, sample collection, nucleic acid extraction, PCR amplification pyrosequencing, and 139 
bioinformatics processing have been published previously (Rogers et al., 2013b; Serisier et al., 2013c; 140 
Rogers et al., 2014) and details of these processes are provided here as Supplementary Methods. 141 
Of the 96 samples previously analysed, 26 were P. aeruginosa-dominated and 34 were H. 142 
influenzae-dominated. It is these 60 samples on which the analysis presented here is based. Patient 143 
details for these patients are shown in Table 1. As described previously, the species-level 144 
identification of P. aeruginosa and H. influenzae two species was confirmed using specific PCR-based 145 
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assays in all instances (Supplementary Methods), with identification by pyrosequencing treated as 146 
presumptive. Where species-level identities were not corroborated by specific assays, identities are 147 
presented at the genus level.  148 
Bacterial taxa within each metacommunity were partitioned into core and satellite groups using the 149 
Poisson distribution test as previously described (van der Gast et al., 2011; Rogers et al., 2013c). 150 
One-way analysis of variance (ANOVA), regression analysis, coefficients of determination (r2), 151 
residuals and significance (P) were calculated using Minitab software (version 16, Minitab, University 152 
Park, PA, USA) as described previously (van der Gast et al., 2011; Rogers et al., 2013c). Canonical 153 
correspondence analysis (CCA), analysis of similarity (ANOSIM), similarity of percentages (SIMPER) 154 
analysis were performed using the PAST (Palaeontological Statistics, version 2.17) program available 155 
from the University of Oslo website link (http://folk.uio.no/ohammer/ past) run by Øyvind Hammer. 156 
Mann Whitney tests were performed using GraphPad Prism (version 5.01, La Jolla, CA 92037 USA). 157 
Where predominant taxa were removed prior to analysis, the remaining relative abundance measures 158 
were rescaled and expressed as percentages. 159 
 160 
Results and Discussion 161 
P. aeruginosa and H. influenzae share certain similarities, for example, they are both Gram 162 
negative, rod-shaped, facultative anaerobic Gammaproteobacteria. However, these common 163 
opportunistic pathogens are associated with very different clinical courses when dominant in 164 
bronchiectasis lung infections. Here the relative abundances of the two predominant species in their 165 
respective groups were high and not significantly different (ANOVA, F1,58 = 0.096, P = 0.758; P. 166 
aeruginosa mean abundance and standard deviation = 87.3 ± 13.4% and H. influenzae = 86.0 ± 167 
17.9%) (Fig. 1). When present in the opposite dominated group the two species were found to be in 168 
only very low abundances (P. aeruginosa = 0.37 ± 1.3% and H. influenzae = 0.56 ± 0.77%; ANOVA, 169 
F1,58 = 0.436, P = 0.511). Furthermore, P. aeruginosa was not detected in 12 from 34 samples of the 170 
H. influenzae group, and 2 from 26 for H. influenzae in the P. aeruginosa group (Fig. 1). This is 171 
consistent with strong competition effects between the two species, moving towards competitive 172 
exclusion of the inferior competitor species; and more so for P. aeruginosa within the H. influenzae 173 
group. If these patterns of dominance and suppression could be purely explained by the process of 174 
interspecies competition then no between group differences in accessory microbiota would be 175 
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expected. However, the analyses performed here demonstrate that taxa present in the microbiota 176 
associated with P. aeruginosa and H. influenzae predominance are significantly divergent. 177 
 The distribution of the two sets of microbiota, as determined by direct ordination using Bray-178 
Curtis similarity measures, is shown in Fig. 2. Where the dominant taxa (P. aeruginosa or H. 179 
influenzae) were included (Fig. 2a), divergence in the distribution of the microbiota was pronounced 180 
and statistically significant (ANOSIM, R = 1, P < 0.0001). However, given the high proportion of total 181 
bacterial abundance that these predominant taxa would account for within the microbiota (Fig. 1), 182 
much of the variation between the two groups will result from their inclusion in the analysis. In order to 183 
assess whether accessory microbiota composition differed significantly between the two groups, the 184 
predominant taxa were removed and the relative abundances of the remaining taxa redistributed and 185 
expressed as percentages. When subjected to ordination analysis, the distribution of the accessory 186 
microbiota composition (Fig. 1b) were not found to be significantly divergent (ANOSM, R = 0.036, P = 187 
0.11). 188 
 Many accessory microbiota taxa are of low relative abundance. The potential contribution to 189 
accessory microbiota of transient bacterial populations within the airways, as opposed to populations 190 
of chronically infective bacteria, is therefore high. In order to reduce the effect of these satellite taxa, 191 
the core microbiota (composed of non-randomly distributed taxa) in each of the two groups was 192 
determined (Fig. 3). This is an approach that has been applied successfully in the analysis of chronic 193 
bacterial infections associated with cystic fibrosis (van der Gast et al., 2011; Rogers et al., 2013a). In 194 
the Haemophilus-dominated group, 9 of the 92 taxa detected were classified as core and 83 as 195 
satellite, and in the Pseudomonas-dominated group, 8 of the 70 taxa detected were classified as core 196 
and 62 as satellite. In each case, the contribution of individual taxa to the core microbiota was 197 
assessed by SIMPER analysis (Tables 2 & S1). Ordination analysis was then performed using the 198 
core taxa, and again the difference between the distribution of the core microbiota that included the 199 
predominant P. aeruginosa and H. influenzae populations was significant (ANOSM, R = 1, P < 0.0001) 200 
(Fig.4a). Moreover, the divergence in the distribution of the core microbiota, readjusted after removal 201 
of the dominant species, was also found to be significantly divergent (ANOSIM, R = 0.07, P = 0.019) 202 
(Fig. 4b). Satellite taxa were not significantly different between the groups (ANOSIM, R = 0.05, P = 203 
0.06). 204 
8 
 
 To assess whether significant differences existed in the relative abundances of specific core 205 
taxa between the P. aeruginosa- and H. influenzae-dominated samples, Mann-Whitney tests were 206 
used and performed on readjusted core taxa abundance data after P. aeruginosa and H. Influenzae 207 
are removed. This process identified Prevotella spp. and Flavobacterium spp. as being significantly 208 
more abundant in the P. aeruginosa-dominated samples (P < 0.0001 and P = 0.003, respectively), 209 
while Neisseria spp. was significantly more abundant in H. influenzae-dominated samples (P < 210 
0.0001). Flavobacterium is a genera that has been reported previously to contribute to bacterial 211 
communities present in chronic lung infections (Rogers et al., 2003; Rogers et al., 2004; van der Gast 212 
et al., 2011; Rogers et al., 2013a) although typically present at low relative abundances. In contrast, 213 
Prevotella spp. have been reported as both common, and often at high abundance in both 214 
bronchiectasis and CF lung infections (Tunney et al., 2008; Field et al., 2010; Stressmann et al., 215 
2012), and otitis media (Brook, 2008). Prevotella spp. appear to be particularly prevalent when co-216 
colonising with P. aeruginosa, a factor that has led to the previous suggestion that a synergistic 217 
relationship exists between P. aeruginosa and members of this genus (Su and Hassett, 2012). The 218 
genus Prevotella is composed of species that are obligate anaerobes. While P. aeruginosa and H. 219 
influenzae are both capable of fermentation and growth under anaerobic conditions (Schobert and 220 
Jahn, 2010; Langereis and Hermans, 2013), the contributions of thick mucoid secretions that P. 221 
aeruginosa can produce in the airways (Ma et al., 2012), a trait not demonstrated by H. influenzae 222 
(Langereis and Hermans, 2013), may contribute to reduced oxygen permeation, leading to the 223 
creation of greater opportunities for the growth of strict anaerobes, such as Prevotella spp. This model 224 
would be consistent with the association observed here between H. influenzae and Neisseria, a genus 225 
of typically aerobic species. 226 
 Canonical correspondence analysis was performed next to assess the extent to which 227 
variance in the microbiota distribution can be accounted for by variation in measures of disease 228 
severity, the presence of comorbidities, and non-antibiotic therapies. The results of these analyses are 229 
shown in Table 3, and additionally superimposed onto Figs 2 & 4. In keeping with previous reports 230 
(Rogers et al., 2014), the presence of P. aeruginosa in samples as the predominant taxon was 231 
associated with high pulmonary exacerbation frequency and poor lung function (low FEV1 percent 232 
predicted), with these factors varying significantly with microbiota distribution. However, whilst such 233 
clinical measures are associated with the presence of P. aeruginosa, these analyses also show that a 234 
9 
 
significant relationship exists with the wider airway microbiota; a significant relationship was identified 235 
here between the variance in core taxa and Leicester Cough Score (a measure of cough symptom 236 
severity).  237 
 Here we observed distributions of predominant taxa consistent with strong interspecific 238 
competition, supporting competitive exclusion in some instances. But we also observed, for instance, 239 
that where P. aeruginosa is the numerically dominant species in a bronchiectasis lung infection it is 240 
associated with a distinct accessory microbiota; suggesting in addition to interspecific competition 241 
there are also direct and/or indirect interactions between the predominant species and the core 242 
microbiota. To some extent, such an effect was also observed for H. influenzae, but was far less 243 
pronounced. However, several different models could explain such interactions. For example, the 244 
predominant species could influence the accessory microbiota composition through modification of the 245 
airway environment and alteration of its selective properties (and vice versa); here, perhaps the fact 246 
that H. influenzae is a common resident of the upper airways means that its presence is less 247 
disruptive to the commonly occurring infective lower airway microbiota. Alternatively, the same change 248 
in the characteristics of the airway could occur through intermediary interaction with the host that 249 
results in an altered inflammatory profile, airway secretion composition, or secretion clearance rate. 250 
Here, a wide array of virulence factors and pro-inflammatory traits possessed by P. aeruginosa 251 
(Sadikot et al., 2005) may contribute to the magnitude of the effect of its predominance on the 252 
accessory airway microbiota. Finally, external influences, such as antibiotic therapy, are likely to 253 
contribute to selective pressures in the airway environment. While there was no significant difference 254 
in historical antibiotic burden in the H .influenzae- and P. aeruginosa-dominated groups, the 255 
contribution of more subtle differences in treatment history cannot be excluded. We suggest that no 256 
single process is responsible for the associations observed, and rather a dynamic interaction between 257 
many different factors give rise to the various types of microbiological scenario seen in vivo. The 258 
potential complexity of these interactions makes their elucidation challenging. However, discerning 259 
their basis is important given that a number of important clinical questions arise from the findings we 260 
present here. These questions include; (1) Could accessory microbiota composition predict 261 
subsequent P. aeruginosa predominance and its associated poor prognosis? (2) Could intervention 262 
aimed at altering the characteristics of the airway environment, or the composition of the accessory 263 
microbiota, reduce the likelihood of P. aeruginosa infection and predominance? (3) What are the 264 
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mechanisms to promote the dominance of H. influenzae, and as a consequence competitively exclude 265 
or suppress P. aeruginosa?  266 
In each case, addressing these questions will require in vitro competition experiments 267 
between the two dominant bacterial species and members of the core microbiota that we have 268 
identified as having likely interactions with P. aeruginosa and H. influenzae. In addition, longitudinal 269 
sample sets that span both clinically and microbiologically important time periods will allow us to better 270 
understand the in vivo mechanisms that lead to predominance of H. influenzae or P. aeruginosa and 271 
its associated worse clinical outcomes. However, obtaining informative longitudinal sample sets in 272 
adult bronchiectasis has significant challenges. Intensive, long-term sample collection would be 273 
required to span rare and unpredictable events, such as the acquisition of P. aeruginosa in a condition 274 
that has relatively slow progression (Martínez-García et al., 2007) and is commonly idiopathic (Anwar 275 
et al., 2013). Given their potential to provide mechanistic insight into the relationship between 276 
recognised airway pathogens, the wider airway microbiota, host immunity, and clinical outcome, such 277 
long-term frequent sample collection represents an important next step. 278 
In conclusion, we present evidence supporting the contribution of both interspecific 279 
competition, and direct and/or indirect interaction between predominant infective taxa and the wider 280 
bacterial community, to determining whether H. influenzae or P. aeruginosa dominates the chronic 281 
lung infections associate with bronchiectasis. Given the prognostic implications of P. aeruginosa 282 
dominance, these findings provide a basis for identifying the mechanisms that underpin this airway 283 
microbial ecology, and perhaps offering novel therapeutic opportunities.  284 
 285 
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Figure legends 443 
Fig. 1. Relative percentage abundances of P. aeruginosa (green circles) and H. influenzae (blue) in 444 
samples from within P. aeruginosa- and H. influenzae-dominated groups (P1-P26 and H1-H34, 445 
respectively). 446 
 447 
Fig. 2. Canonical correspondence biplots for microbiota (a) with and (b) without Pseudomonas and 448 
Haemophilus included. Dots represent microbiota samples from the Pseudomonas (denoted with 449 
green filled circles) and Haemophilus (blue filled squares) groups. In each instance, the 95 % 450 
concentration ellipses are given for the Pseudomonas (green) and Haemophilus (blue) groups. Biplot 451 
lines for the clinical variables included in the analyses show the direction of increase for each variable, 452 
and the length of each line indicates the degree of correlation with the ordination axes. CCA field 453 
labels: “AH” – antihypertensive, “LABA/ICS” – long acting β-agonist, “SABA” – short acting β-agonist, 454 
“prior IE” – number of pulmonary exacerbations in the prior twelve months. Percentage of community 455 
variation explained by each axis is given in parentheses. 456 
 457 
Fig. 3. Distribution and dispersal of bacterial taxa among Haemophilus- and Pseudomonas-dominated 458 
microbiota samples. (a & b) The number of samples for which each detected bacterial taxon (open 459 
circles) was observed, plotted against the abundance (log10 scale) of that species among all samples 460 
within each group ((a) Haemophilus group, r2 = 0.27, F1,92 = 33.2, P < 0.0001; and (b) Pseudomonas 461 
group, r2 = 0.33, F1,68 = 33.5, P < 0.0001). Also given are dispersal plots to identify which bacterial taxa 462 
are randomly distributed within the (c) Haemophilus and (d) Pseudomonas groups; a measure used to 463 
assign core versus satellite status. Index of dispersion was calculated as the ratio of variance to mean 464 
of abundance for each taxon within each group and plotted for each sample. The line depicts the 2.5 465 
% confidence limit for the χ2 distribution. Taxa that fall below this line are randomly distributed and 466 
were considered satellite taxa, whereas those that are above the line are non-randomly distributed 467 
and were considered core taxa. The 97.5 % confidence limit was not plotted, as no taxon fell below 468 
that line. 469 
 470 
Fig. 4. Canonical correspondence biplots for core microbiota (a) with and (b) without Pseudomonas 471 
and Haemophilus included. Dots represent core microbiota from the Pseudomonas (denoted with 472 
17 
 
green filled circles) and Haemophilus (blue filled squares) groups. In each instance, the 95 % 473 
concentration ellipses are given for the Pseudomonas (green) and Haemophilus (blue) groups. Biplot 474 
lines for the clinical variables included in the analyses show the direction of increase for each variable, 475 
and the length of each line indicates the degree of correlation with the ordination axes. CCA field 476 
labels: “AH” - antihypertensive, “LCS” – Leicester cough score, “prior IE” – number of pulmonary 477 
exacerbations in the prior twelve months. Percentage of community variation explained by each axis is 478 
given in parentheses. 479 




Table 1. Clinical, treatment and comorbidity data for patient population. FEV1%* – forced expiratory 
volume in one second, expressed as a percentage of predicted and measured following 
administration of a bronchodilator; SGRQ, St George’s Respiratory Questionnaire – range 1-100, 
lower scores indicate better quality of life. Leicester cough score – lower scores indicate worse cough 
symptoms. 
 
P. aeruginosa H. influenzae 
Gender (male:female) 6:20 16:18 
Clinical measures of disease Range Mean (± SD) Range Mean (± SD) 
     FEV1%* 30.7-94.2 60.5 (± 18.1) 37.2-114.7 71.2 (± 15.1) 
     Duration of bronchiectasis (years) 1-70 45.4 (± 19.6) 10-65 45.4 (± 17.5) 
     Pulmonary exacerbations in prior 
     12 months 2-12 6.3 (± 3.0) 2-7 3.4 (± 1.3) 
     Leicester cough score 5.5-20.2 14.8 (± 3.5) 7.7-19.9 15.6 (± 2.6) 
     SGRQ total 8.6-79.6 39.9 (± 16.6) 14.9-58.9 36.7 (± 14.0) 
     Six minute walk test 291-650 488.7 (± 85.1) 275-710 519.6 (± 101.6) 
     C-reactive protein (mg/litre) 0-21 6.8 (± 6.0) 0-19 7.1 (± 6.1) 
     Induced sputum IL-8 (ng/ml) 27.4-1053.8 337.6 (± 340.3) 28.8-1326.7 275.2 (± 295.7) 
     Induced sputum IL-1β (ng/ml) 0.25-36.2 9.8 (± 10.7) 0.6-115.8 11.4 (± 22.3) 
Treatment 
     Short acting β-agonist 14 10 
     Inhaled corticosteroid 16 17 
     Inhaled corticosteroid + long 
     acting β-agonist 13 10 
     Anti-cholinergics 6 2 
     Aspirin 3 9 
     Beta blocker 0 3 
     Nasal steroids 2 4 
     Prednisolone 3 1 
     Antihypertensive 9 16 
Comorbidity 
     Cerebrovascular disease 1 4 
     Heart disease 2  4  
     Hypertension 6 14 
     Diabetes 1 0 
 
Table 2. Similarity of percentages (SIMPER) analysis of bacterial community dissimilarity (Bray-
Curtis) between core taxa groups without Pseudomonas and Haemophilus. Given is mean % 
abundance of sequences for each taxon across the samples they were observed to occupy. Analysis 
was based on an average of 10647 sequences per sample (SD 5070, range 2395-28916). Also given 
is the average dissimilarity between samples (overall mean = 61.9%). Percentage contribution is the 
mean contribution divided by mean dissimilarity across samples. SIMPER analysis with 
Pseudomonas and Haemophilus is presented in Table S1. 
 
% Mean abundance Samples detected in 
Taxon Pseudomonas group 
Haemophilus 
group 
Pseudomonas 
group 
Haemophilus 
group 
Average 
dissimilarity 
% 
Contribution 
Cumulative 
% 
Prevotella 31.9 31 23 27 14.96 24.17 24.17 
Veillonella 20.8 26.7 25 30 11.85 19.14 43.31 
Streptococcus 13.2 18.3 22 26 10.51 16.99 60.30 
Moraxella 14 4.9 10 5 8.69 14.04 74.34 
Neisseria 7.8 13.6 18 25 7.59 12.26 86.60 
Flavobacterium 8.7 0 17 0 4.35 7.02 93.62 
Leptotrichia 3.6 2.0 16 18 2.22 3.59 97.21 
Fusobacterium 0 3.5 0 11 1.72 2.79 100 
 
Table 3. Canonical correspondence analyses for determination of percent variation in lung microbiota 
from bronchiectasis subjects by clinical variables. LABA, long acting β-agonist; ICS, inhaled 
corticosteroid; SABA, short acting β-agonist. 
 
Whole microbiota 
Whole microbiota without P & 
H Core microbiota 
Core microbiota without P & 
H 
Variable 
% of 
variance 
Probabilit
y % of variance Probability 
% of 
variance 
Probabilit
y % of variance Probability 
Prior Exacerbations 11.35 0.01 2.35 0.02 13.8 0.01 2.7 0.01 
FEV1 % predicted 4.60 0.01 2.41 0.01 5.5 0.01 4.9 0.01 
Hypertension 3.08 0.01 - - 3.5 0.01 2.7 0.01 
Gender 3.01 0.01 - - 3.4 0.01 - - 
Anti-Hypertensive - - 2.20 0.01 - - 2.3 0.01 
LABA + ICS - - 1.81 0.02 - - - - 
SABA - - 1.54 0.02 - - - - 
Leicester cough 
score - - - - - - 3.1 0.02 
 
Table S1. Similarity of percentages (SIMPER) analysis of bacterial community dissimilarity (Bray-
Curtis) between core taxa groups with Pseudomonas and Haemophilus. Given is mean % abundance 
of sequences for each taxon across the samples they were observed to occupy. Analysis was based 
on an average of 10647 sequences per sample (SD 5070, range 2395-28916). Also given is the 
average dissimilarity between samples (overall mean = 61.9%). Percentage contribution is the mean 
contribution divided by mean dissimilarity across samples. 
 
% Mean abundance Samples detected in 
Taxon Pseudomonas group 
Haemophilus 
group 
Pseudomonas 
group 
Haemophilus 
group 
Average 
dissimilarity 
% 
Contribution 
Cumulative 
% 
Pseudomonas 87.3 0.37 26 22 44.44 45.53 45.53 
Haemophilus 0.56 86 24 34 43.93 45.01 90.54 
Prevotella 2.61 4.14 23 27 2.51 2.57 93.11 
Streptococcus 1.51 2.35 22 26 1.69 1.73 94.84 
Veillonella 1.44 2.8 25 30 1.67 1.71 96.55 
Flavobacterium 2.38 0 17 0 1.21 1.24 97.79 
Moraxella 1.18 0.54 10 5 0.83 0.85 98.65 
Neisseria 0.74 0.97 18 25 0.74 0.75 99.40 
Leptotrichia 0.57 0.20 16 18 0.35 0.36 99.77 
Fusobacterium 0 0.45 0 11 0.23 0.23 100 
 
 1
Supplementary Methods 1 
Samples were collected from participants in the Bronchiectasis and Low-dosen Erythromycin Study 2 
(BLESS) trial (Serisier et al., 2013). Adult patients aged 20 to 85 years were eligible if they had 3 
bronchiectasis documented by high-resolution computed tomographic scan, at least 2 separate 4 
pulmonary exacerbations requiring supplemental systemic antibiotic therapy in the preceding 12 5 
months, and daily sputum production. Participants were required to have been clinically stable for at 6 
least 4 weeks prior to enrolment (defined as no symptoms of exacerbation, no requirement for 7 
supplemental antibiotic therapy, and forced expiratory volume in the firs second of expiration [FEV1] 8 
within 10% of best recently recorded value where available). Exclusion criteria included CF, current 9 
mycobacterial disease or bronchopulmonary aspergillosis, any reversible cause for exacerbations, 10 
maintenance oral antibiotic prophylaxis, prior macrolide use except short-term, changes to 11 
medications in the preceding 4 weeks, cigarette smoking within 6 months, and medications or 12 
comorbidities with the potential for important interactions with erythromycin. All participants required 13 
negative results from sputum mycobacterial cultures prior to randomization. The study was approved 14 
by the Mater Health Service human research ethics committee, and all participants provided written, 15 
informed consent. 16 
 17 
Sample collection 18 
Subjects were instructed to perform their usual chest physiotherapy regime on the morning of the 19 
sputum induction procedure. Prior to commencement of hypertonic saline inhalation, any spontaneous 20 
sputum expectorated was collected for standard culture. Sputum induction (SI) was performed after 21 
inhalation of 400 ug of albuterol, using 4.5% hypertonic saline nebulised from an ultrasonic nebuliser 22 
(output >1 mL/ min) for 20 minutes in 4 periods of 5 minutes each, according to the standardised 23 
protocol recommended by the European Respiratory Society taskforce [Paggiaro et al., 2002] 24 
Following mouth-rinsing and expectoration, sputum was collected following each nebulisation period, 25 
on each occasion preceded immediately by spirometry. The first sputum sample was refrigerated 26 
immediately following collection and frozen at -80 °C within an hour. A cold chain was maintained up 27 
until the point of DNA extraction. 28 
 29 
DNA extraction protocol 30 
 2
Nucleic acid extractions were performed on 500 μL cell suspensions. Guanidinium thiocyanate–1 
EDTA–sarkosyl (500 μL) and PBS (500 μL), pH 8.0, were added to samples. Cell disruption was 2 
achieved using a Fastprep-24 Instrument (MP Biomedicals Europe, Illkirch, France) 6.5 m/s, 60 s, 3 
followed by incubation at 90 °C for 1 min and −20 °C for 5 min. Cell debris was pelleted by 4 
centrifugation at 12 000 × g for 2 min at 4 °C. Supernatant was transferred to a fresh microfuge tube. 5 
NaCl (to a final concentration of 0.5 mol/L and polyethylene glycol (to a final concentration of 15%) 6 
were added and DNA precipitated at 4 °C for 30 min. DNA was pelleted by centrifugation at 12 000 × g 7 
for 2min at 4 °C and resuspended in 300 μL of sterile distilled water. Samples were heated at 90 °C for 8 
30 s and vortexed. Phenol/chloroform (1:1) (300 μL) was added, and samples were vortexed for 20 s 9 
before centrifugation at 12 000 × g at 4 °C for 3min. The upper phase was then transferred to a fresh 10 
microfuge tube. Total DNA was then precipitated by the addition of an equal volume of isopropanol, a 11 
0.1-volume 10 mol/L ammonium acetate, and 1 μL of GenElute linear polyacrylamide (Sigma-Aldrich, 12 
Gillingham, UK) and incubated at −20 °C for 25 min. DNA was pelleted by centrifugation at 12 000 × g 13 
at 4 °C for 5 min. Pelleted DNA was then washed 3 times in 70% ethanol, dried, and resuspended in 14 
50 μL of sterile distilled water. DNA extracts were quantified using the Picodrop Microlitre 15 
Spectrophotometer (GRI, Braintree, UK). Negative controls, consisting of sterile water, were included 16 
in the PMA treatment, DNA extraction, and PCR amplification steps. 17 
 18 
Pyrosequencing 19 
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) was performed as described 20 
previously using Gray28F 5'-TTTGATCNTGGCTCAG-3' and Gray519r 5'-21 
GTNTTACNGCGGCKGCTG-3'). Initial generation of the sequencing library involved a one-step PCR 22 
of 30 cycles, using a mixture of Hot Start and HotStar high fidelity Taq DNA polymerase, as described 23 
previously (4). Tag-encoded FLX amplicon pyrosequencing analyses utilized Roche 454 FLX 24 
instrument with Titanium reagents, titanium procedures performed at the Research and Testing 25 
Laboratory (Lubbock, TX) using RTL protocols (www.researchandtesting.com).  26 
Following sequencing, all failed sequence reads, low quality sequence ends and tags and primers 27 
were removed. Sequences with ambiguous base calls, sequences with homopolymers > 6bp were 28 
removed. Further, any non-bacterial ribosomal sequences and chimeras using B2C2 (Dowd et al., 29 
2008) as described previously (Dowd et al., 2008). To determine the identity of bacterial species in the 30 
 3
remaining sequences, sequences were de-noised, assembled into OUT clusters at 97% identity, and 1 
queried using a distributed .NEt algorithm that utilizes Blastn+ (KrakenBLAST www.krakenblast.com) 2 
against a database of high quality 16S rRNA gene bacterial sequences. Using a .NET and C# analysis 3 
pipeline the resulting BLASTn+ outputs were compiled, data reduction analysis performed, and 4 
sequence identity classification carried out, as described previously (Dowd et al., 2008). 5 
 6 
Quantitative PCR 7 
P. aeruginosa density was determined using a Taqman assay, in which a 117 bp region between 8 
positions 330 to 447 of the P. aeruginosa OprL gene was amplified, as described previously 9 
(Feizabadi et al., 2010). Primers (PsF: 5'-CGAGTACAACATGGCTCTGG-3', EubR: 5'- 10 
ACCGGACGCTCTTTACCATA-3') were used at a concentration of 500 nM each, and the probe 11 
(EubPr: 5'-FAM- CCTGCAGCACCAGGTAGCGC -TAMRA-3') at a concentration of 250 nM. All 12 
reactions were carried out in a total volume of 20 μl containing primers at a concentration of 500 nM 13 
each, probe concentration of 250 nM, 1 μl of template and LightCycler 480 Probes Master (Roche 14 
Diagnostics GmbH, Mannheim, Germany) at 1x final concentration. Quantitative PCR assays were 15 
carried out using the Rotor-Gene Q (Qiagen, Crawley, UK) with a temperature profile of 95 °C for 5 16 
min, followed by 45 cycles at 95 °C for 15 s and 58 °C for 45 s. Nutrient broth culture of P. aeruginosa 17 
(NCTC 12934/ATCC 27853) was incubated at 37 °C for 16 h, with cfu/ml estimated by incubation of 18 
dilutions (n=4) on Nutrient agar at 37° for 24 h, followed by colony counts. DNA was extracted from 19 
tenfold dilutions of the broth culture in the same way as for the sputum samples, and RT-PCR was 20 
carried out as above on the DNA extracts. The standard curve generated using P. aeruginosa (qPCR 21 
efficiency = 1.20; R2 value = 0.996) was used as reference to allow direct comparisons to be made by 22 
the Rotor Gene Q-series Software (Qiagen, Crawley, UK). 23 
H. influenzae density was determined using a Taqman assay, in which a 90-bp region between 24 
positions 518 to 608 of the H. influenzae Hel gene was amplified, using primers (HelSF: 5'-25 
CCGGGTGCGGTAGAATTTAATAA-3', EubR: 5'-CTGATTTTTCAGTGCTGTCTTTGC-3') were used at 26 
a concentration of 100 nM each, and the probe (EubPr: 5'-FAM- 27 
ACAGCCACAACGGTAAAGTGTTCTACG-TAMRA-3') (Long, 2011). All PCR reactions were carried 28 
out in a total volume of 20 μl containing primers and probe at a concentration of 1000:500:200 nM 29 
(HelSF: HelSR; HelSPr), 1 μl of template and LightCycler 480 Probes Master (Roche Diagnostics 30 
 4
GmbH, Mannheim, Germany) at 1x final concentration. Quantitative PCR assays were carried out 1 
using the Rotor-Gene Q (Qiagen, Crawley, UK) with a temperature profile of 95 °C for 5 min, followed 2 
by 45 cycles at 95 °C for 15 s and 60 °C for 60 s. A standard curve was generated by qPCR settings 3 
as above using H. influenzae DNA extract obtained from the Health Protection Agency (H. influenza 4 
clinical isolate, chronic respiratory infection, 2012). H. influenza load (cfu/ml) was determined by direct 5 
comparison with the standard curve (qPCR efficiency = 1.05; R2 value = 0.997) using the Rotor Gene 6 
Q-series Software (Qiagen, Crawley, UK). 7 
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